The company has demonstrably boosted its progress of an new solution for cardiac amyloidosis, utilizing Attruby. Early trial results reveals significant benefits for patients affected by this debilitating condition. https://biotech117577.dgbloggers.com/42561062/bridgebio-improves-cardiac-amyloidosis-treatment-through-the-drug